New York State Medical Treatment Guidelines for Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs) in workers compensation patients

The guidelines provided by the New York State Workers Compensation Board offer general principles for the use of Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs). These directives aim to assist healthcare professionals in determining appropriate strategies for prescribing these medications, which act by inhibiting the reuptake of both serotonin and norepinephrine, as part of a comprehensive treatment plan.

Healthcare practitioners specializing in Serotonin–Norepinephrine Reuptake Inhibitors can rely on the guidance from the Workers Compensation Board to make well-informed decisions about the most suitable approaches for utilizing these medications in the care of their patients.

It is crucial to emphasize that these guidelines are not intended to replace clinical judgment or professional expertise. The ultimate decision regarding the use of Serotonin–Norepinephrine Reuptake Inhibitors should involve collaboration between the patient and their healthcare provider.

Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs)

Venlafaxine is a recommended option for treating patients with PTSD, especially when symptoms are significant enough to necessitate medication.

It’s a suitable choice unless there’s a lack of efficacy, adverse effects, non-compliance, or if the resolution of PTSD reaches a point where medication is no longer necessary. Exploring the evidence supporting the use of Venlafaxine can provide a more comprehensive understanding of its effectiveness.

Skip to content